The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
Open accessAbstract
There are no disease-modifying treatments for adult human neurodegenerative diseases. Here we test RNA-targeted therapies in two mouse models of spinocerebellar ataxia type 2 (SCA2), an autosomal dominant polyglutamine disease. Both models recreate the progressive adult-onset dysfunction and degeneration of a neuronal network that are seen in patients, including decreased firing frequency of cerebellar Purkinje cells and a decline in motor function. We developed a potential therapy directed at the ATXN2 gene by screening 152 antisense oligonucleotides (ASOs). The most promising oligonucleotide, ASO7, downregulated ATXN2 mRNA and protein, which resulted in delayed onset of the SCA2 phenotype. After delivery by intracerebroventricular injection to ATXN2-Q127 mice, ASO7 localized to Purkinje cells, reduced cerebellar ATXN2 expression below 75% for more than 10 weeks without microglial activation, and reduced the levels of cerebellar ATXN2. Treatment of symptomatic mice with ASO7 improved motor function compared to saline-treated mice. ASO7 had a similar effect in the BAC-Q72 SCA2 mouse model, and in both mouse models it normalized protein levels of several SCA2-related proteins expressed in Purkinje cells, including Rgs8, Pcp2, Pcp4, Homer3, Cep76 and Fam107b. Notably, the firing frequency of Purkinje cells returned to normal even when treatment was initiated more than 12 weeks after the onset of the motor phenotype in BAC-Q72 mice. These findings support ASOs as a promising approach for treating some human neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Due to the precision afforded by complementary binding of an ASO to its target transcript of interest, ASOs have emerged as an invaluable tool in specifically altering levels and/or processing of a variety of proteins involved in neurodegenerative diseases, most of which have been the disease-causing protein itself (38, 51–54).”
From Reduction of nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43–related neurodegeneration (2023) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia
Xia, H., Mao, Q.-W., Eliason, S., Harper, S., Martins, I. H., Orr, H., Paulson, H., Yang, L., Kotin, R., & Davidson, B. (2004) · Nature Medicine · doi:10.1038/nm1076 · Cited by 689
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citationTherapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice
Becker, L. A., Huang, B., Bieri, G., Ma, R., Knowles, D. A., Jafar-Nejad, P., Messing, J., Kim, H. J., Soriano, A., Auburger, G., et al. (2017) · Nature · doi:10.1038/nature22038 · Cited by 571
Self-citationSwayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 483
Self-citationThe genetics and neuropathology of Parkinson’s disease
Houlden, H., & Singleton, A. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1013-5 · Cited by 331
Huynh, D. P., Figueroa, K. P., Hoang, N., & Pulst, S.-M. (2000) · Nature Genetics · doi:10.1038/79162 · Cited by 330
Self-citationDeranged Calcium Signaling and Neurodegeneration in Spinocerebellar Ataxia Type 2
Liu, J., Tang, T.-S., Tu, H., Nelson, O. L., Herndon, E., Huynh, D. P., Pulst, S. M., & Борисович, Б. И. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0660-09.2009 · Cited by 299
Self-citationCarroll, J. B., Warby, S. C., Southwell, A. L., Doty, C. N., Greenlee, S., Skotte, N. H., Hung, G., Bennett, C. F., Freier, S. M., & Hayden, M. R. (2011) · Molecular Therapy · doi:10.1038/mt.2011.201 · Cited by 293
Self-citationHansen, S. T., Meera, P., Otis, T. S., & Pulst, S. M. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds427 · Cited by 173
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–318 of 318
Bewegungsstörungen und Erkrankungen des Kleinhirns
Franke, C., Storch, A., & Kamm, C. (2022) · Elsevier eBooks · doi:10.1016/b978-3-437-21884-2.00008-8
Cell replacement in the degenerating cerebellum: a historical essay of discovery
Triarhou, L. C. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13492-4
Advances in Diagnosis and Treatment of Hereditary Ataxias in Children
金, 璐. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161074
Approaches to the treatment of autosomal-dominant spinocerebellar ataxias
Kononova, S. K. (2025) · Yakut Medical Journal · doi:10.25789/ymj.2025.92.24
Blood glucose homeostasis in patients with mild to moderate Spinocerebellar Ataxia type 2Preprint
Aguilera‐Rodríguez, R., Almaguer‐Gotay, D., Sosa, A. Á., Anidos-Machado, M., Silva-Ricardo, Y., Cuello‐Almarales, D., Estupiñán‐Rodríguez, A., & Almaguer‐Mederos, L. E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.25.701567
Pan-biological characteristics of ataxin-2 protein
Conceição, A., & Nóbrega, C. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00751
IL-4/IL-4Rα signaling activates PPARγ to promote oligodendrocyte differentiation and remyelination
Yin, Y., Li, S.-H., Yu, F.-L., Zhang, Y., Du, R.-Y., Li, H., Zou, Y.-R., Zhang, L.-J., Zhang, Y., & Han, B. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106568
Genotype-phenotype correlation in inherited retinal diseases
Nassisi, M. (2022) · theses.fr (ABES) · doi:10.70675/1aca6579zf22az4618z9874z7fe69f357e91
Pulst, S. M., Paul, S., Nguyen, H. T., Dansithong, W., Figueroa, K. P., Gandelman, M., Bonini, N. M., & Scoles, D. R. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08830-x
Self-citationModels of Spinocerebellar Ataxias
Scoles, D. R., Kapl, S., Choudhury, N. R., Pulst, S. M., & Gandelman, M. (2026) · Contemporary clinical neuroscience · doi:10.1007/978-3-032-18296-8_19
Self-citationSoto, I., Bonomo, M., Nelthrope, B. S., Carr, B. D., Palmer, E., Sierra, M., Ertürk, İ., Peppercorn, D., Cox, E., Vasconcellos, T. K., et al. (2026) · Annals of Neurology · doi:10.1002/ana.78282
Wang, X., Lee, H., Le, A., Turhan, B., Hu, N., Garcia, P. S., Cao, X., Liu, D. K., Ali, T. A., Zhang, N., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.12.731989
Gene therapy for spinocerebellar ataxias
Eo, H., Bok, E., Lee, H.-W., Suk, K., Kim, H., Kim, J., & Kim, S. R. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.06.008
Hao, Y., & Hao, X. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1921210
Toward the clinical application of long-read sequencing in repeat-expansion disorders
Benarroch, L., Pešović, J., Rossato, M., Chen, Z., Lucas, M. C., Cogan, G., Rajan‐Babu, I., Prokosch, V., Zarouchlioti, C., Carlomagno, M., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02694-9
Aguilera‐Rodríguez, R., Almaguer‐Gotay, D., Sosa, A. Á., Anidos-Machado, M., Silva-Ricardo, Y., Cuello‐Almarales, D., Estupiñán‐Rodríguez, A., & Almaguer‐Mederos, L. E. (2026) · The Cerebellum · doi:10.1007/s12311-026-02076-1
Gene therapy in spinocerebellar ataxia (SCA)
Aslan, F. Ş., & Akyüz, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40467-2.00001-4
Metadata
- Authors
- Scoles, D. R., Meera, P., Schneider, M. D., Paul, S., Dansithong, W., Figueroa, K. P., Hung, G., Rigo, F., Bennett, C. F., Otis, T. S., & Pulst, S. M.
- Affiliations
- University of Utah (US)
- University of California, Los Angeles (US)
- Ionis Pharmaceuticals (United States) (US)
- Corresponding author
- Scoles, Daniel R.
- Pulst, Stefan M.
- ORCID
- Venue
- Nature
- Published
- 2017-04-12
- Volume
- 544
- Issue
- 7650
- Pages
- 362-366
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6625650
- OpenAlex
- W2606911774
- Cited by
- 319
- References
- 31
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 26 · 2023: 28 · 2022: 39 · 2021: 37 · 2020: 37 · 2019: 43 · 2018: 45 · 2017: 21
- FWCI
- 19.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Target ALS
- National Institute of Neurological Disorders and Stroke (U01NS103883, R01NS033123, R01NS090930, R21NS081182, RC4NS073009, R56NS033123, R01NS097903, R37NS033123, R21NS103009)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- spinocerebellar ataxia type 2, antisense oligonucleotides, ATXN2, polyglutamine expansion, Purkinje cells, TDP-43 aggregation, amyotrophic lateral sclerosis, RNA-targeted therapeutics, neurodegeneration, mouse model, motor function, lifespan
- MeSH terms
- Ataxin-2, Action Potentials, Animals, Disease Models, Animal, Female, Gene Expression Regulation, Humans, Male, Mice, Transgenic, Movement, Phenotype, Purkinje Cells, RNA, Messenger, Oligonucleotides, Antisense, Spinocerebellar Ataxias, Rotarod Performance Test, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
